FDMT Q4 2022 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+1255.4% YoY

Gross Profit

-$20M-1624.1% margin

Operating Income

-$29M-2303.1% margin

Net Income

-$27M-2195.6% margin

EPS (Diluted)

$-0.84

QoQ Revenue Growth

+149.4%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$262M

Total Liabilities

$31M

Stockholders' Equity

$231M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$92,000	+1255.4%
Gross Profit	-$20M	-$17M	-16.2%
Operating Income	-$29M	-$25M	-16.0%
Net Income	-$27M	-$25M	-9.2%

Geographic Segments

NETHERLANDS

$1M100%

UNITED STATES

$2,0000%